Regenxbio gene therapy refiling plan derailed by FDA hold

The FDA has placed a clinical hold on Regenxbio's gene therapy RGX-121 for Hunter syndrome due to asymptomatic spine MRI findings, delaying the company's plans to refile for approval.

This Wire brief sits within Fusion42's coverage of Biotech, and 6 sources have reported it.